{
    "info": {
        "nct_id": "NCT03707938",
        "official_title": "BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) With Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLC",
        "inclusion_criteria": "1. Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)\n2. Documented ALK re-arrangement as detected by: (1) FISH, (2) IHC, (3) tissue NGS, or (4) cfDNA NGS\n3. Subjects can be enrolled as (1) TKI naïve or (2) after ≤ 8 weeks of first-line brigatinib treatment without disease progression.\n4. Candidate for local consolidative therapy to at least one site of residual disease\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n6. Males or females aged at least 18 years.\n7. Adequate organ function laboratory values, defined as:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or at least 1500/mm3 or at least 1.5 x 109/L\n   2. Platelet count at least 75,000/mm3 or at least 75 x 109/L\n   3. Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline\n   4. Serum creatinine ≤ 1.5 × ULN or ≥ 60 mL/minute for subjects with creatinine levels > 1.5 × the institutional ULN\n   5. Serum total bilirubin less than or equal to ≤ 1.5 × ULN or direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 × ULN\n   6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN except for subjects with liver mets for whom ALT and AST should be ≤ 5× ULN\n   7. International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants\n   8. Activated PTT (aPTT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant\n8. Female patients of childbearing potential must have a negative pregnancy test documented at time of screening.\n9. Female patients who:\n\n   1. Are postmenopausal for at least 1 year before the screening visit, OR\n   2. Are surgically sterile, OR\n   3. If they are of childbearing potential, agree to use a highly effective method of contraception from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse\n10. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:\n\n    1. Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or\n    2. Agree to completely abstain from heterosexual intercourse\n11. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.\n12. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 2 years elapsed since the diagnosis of the other primary malignancy.\n2. Previously received any prior TKI, including ALK-targeted TKIs. Note: on-going first-line brigatinib use as specified in the Inclusion criteria is allowed.\n3. Previously received more than 1 regimen of chemotherapy or immunotherapy for locally advanced or metastatic disease. Note that history of consolidative immunotherapy after concurrent chemoradiotherapy (for locally advanced disease) is allowed.\n4. Symptomatic CNS metastasis. Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted.\n5. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed.\n6. The presence of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis at screening.\n7. Have a known or suspected hypersensitivity to brigatinib or its excipients.\n8. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition that could affect oral absorption of the study drug.\n9. Be pregnant, planning a pregnancy, or breastfeeding.\n10. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:\n\n    1. Myocardial infarction (MI) within 6 months prior to the first dose of study drug\n    2. Unstable angina within 6 months prior to first dose of study drug\n    3. Decompensated congestive heart failure (CHF) within 6 months prior to first dose of study drug\n    4. History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician\n    5. Any history of ventricular arrhythmia\n    6. Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose of study drug\n11. Have uncontrolled hypertension. Patients with hypertension should be under treatment on study entry to control blood pressure\n12. Have an ongoing or active infection, including, but not limited to, the requirement for intravenous (IV) antibiotics.\n13. Have a known history of human immunodeficiency virus (HIV) infection. Testing is not required in the absence of history.\n14. Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the study drug.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "2. Agree to completely abstain from heterosexual intercourse",
                "criterions": [
                    {
                        "exact_snippets": "Agree to completely abstain from heterosexual intercourse",
                        "criterion": "heterosexual intercourse",
                        "requirement": {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Agree to completely abstain from heterosexual intercourse",
                        "criterion": "heterosexual intercourse",
                        "requirement": {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Adequate organ function laboratory values, defined as:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate organ function laboratory values",
                        "criterion": "organ function laboratory values",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate organ function laboratory values",
                        "criterion": "organ function laboratory values",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:",
                "criterions": [
                    {
                        "exact_snippets": "Male patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    },
                    {
                        "exact_snippets": "even if surgically sterilized (i.e., status post-vasectomy)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Male patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        }
                    },
                    {
                        "exact_snippets": "even if surgically sterilized (i.e., status post-vasectomy)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants",
                "criterions": [
                    {
                        "exact_snippets": "International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy",
                        "criterion": "INR or PT",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants",
                        "criterion": "PT or PTT (for subjects on anticoagulant therapy)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "not_criteria": {
                        "exact_snippets": "unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants",
                        "criterion": "PT or PTT (for subjects on anticoagulant therapy)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    }
                },
                "then_criteria": {
                    "exact_snippets": "International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy",
                    "criterion": "INR or PT",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 1.5,
                            "unit": "ULN"
                        }
                    }
                },
                "else_criteria": {
                    "exact_snippets": "unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants",
                    "criterion": "PT or PTT (for subjects on anticoagulant therapy)",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": "within therapeutic range of intended use of anticoagulants"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline",
                        "criterion": "hemoglobin (Hb) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline",
                        "criterion": "hemoglobin (Hb) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5.69,
                                "unit": "mmol/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline",
                        "criterion": "hemoglobin (Hb) level",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at baseline"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline",
                                "criterion": "hemoglobin (Hb) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 9,
                                        "unit": "g/dL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline",
                                "criterion": "hemoglobin (Hb) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 5.69,
                                        "unit": "mmol/L"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline",
                        "criterion": "hemoglobin (Hb) level",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at baseline"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Subjects can be enrolled as (1) TKI naïve or (2) after ≤ 8 weeks of first-line brigatinib treatment without disease progression.",
                "criterions": [
                    {
                        "exact_snippets": "TKI naïve",
                        "criterion": "prior TKI treatment",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "after ≤ 8 weeks of first-line brigatinib treatment without disease progression",
                        "criterion": "first-line brigatinib treatment",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "after ≤ 8 weeks of first-line brigatinib treatment without disease progression",
                        "criterion": "first-line brigatinib treatment",
                        "requirement": {
                            "requirement_type": "disease progression",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "TKI naïve",
                        "criterion": "prior TKI treatment",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "after ≤ 8 weeks of first-line brigatinib treatment without disease progression",
                                "criterion": "first-line brigatinib treatment",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "after ≤ 8 weeks of first-line brigatinib treatment without disease progression",
                                "criterion": "first-line brigatinib treatment",
                                "requirement": {
                                    "requirement_type": "disease progression",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Are postmenopausal for at least 1 year before the screening visit, OR",
                "criterions": [
                    {
                        "exact_snippets": "Are postmenopausal for at least 1 year before the screening visit",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        }
                    },
                    {
                        "exact_snippets": "Are postmenopausal for at least 1 year before the screening visit",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Are postmenopausal for at least 1 year before the screening visit",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        }
                    },
                    {
                        "exact_snippets": "Are postmenopausal for at least 1 year before the screening visit",
                        "criterion": "menopausal status",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or at least 1500/mm3 or at least 1.5 x 109/L",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or at least 1500/mm3 or at least 1.5 x 109/L",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1.5,
                                        "unit": "x 10^9/L"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 1500,
                                        "unit": "mm3"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or at least 1500/mm3 or at least 1.5 x 109/L",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1.5,
                                        "unit": "x 10^9/L"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 1500,
                                        "unit": "mm3"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN except for subjects with liver mets for whom ALT and AST should be ≤ 5× ULN",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 × ULN except for subjects with liver mets for whom ALT ... should be ≤ 5× ULN",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "aspartate aminotransferase (AST) ... ≤ 2.5 × ULN except for subjects with liver mets for whom ... AST should be ≤ 5× ULN",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "subjects with liver mets ... ALT and AST should be ≤ 5× ULN",
                        "criterion": "ALT and AST levels in subjects with liver metastases",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "subjects with liver mets ... ALT and AST should be ≤ 5× ULN",
                    "criterion": "ALT and AST levels in subjects with liver metastases",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": "<=",
                                    "value": 5,
                                    "unit": "ULN"
                                }
                            ]
                        }
                    }
                },
                "then_criteria": null,
                "else_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 × ULN except for subjects with liver mets for whom ALT ... should be ≤ 5× ULN",
                            "criterion": "alanine aminotransferase (ALT) level",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "comparisons": [
                                        {
                                            "operator": "<=",
                                            "value": 2.5,
                                            "unit": "ULN"
                                        }
                                    ]
                                }
                            }
                        },
                        {
                            "exact_snippets": "aspartate aminotransferase (AST) ... ≤ 2.5 × ULN except for subjects with liver mets for whom ... AST should be ≤ 5× ULN",
                            "criterion": "aspartate aminotransferase (AST) level",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "comparisons": [
                                        {
                                            "operator": "<=",
                                            "value": 2.5,
                                            "unit": "ULN"
                                        }
                                    ]
                                }
                            }
                        }
                    ]
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Candidate for local consolidative therapy to at least one site of residual disease",
                "criterions": [
                    {
                        "exact_snippets": "Candidate for local consolidative therapy to at least one site of residual disease",
                        "criterion": "candidate for local consolidative therapy",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "to at least one site of residual disease",
                        "criterion": "residual disease site",
                        "requirement": {
                            "requirement_type": "number of sites eligible for local consolidative therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Candidate for local consolidative therapy to at least one site of residual disease",
                        "criterion": "candidate for local consolidative therapy",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "to at least one site of residual disease",
                        "criterion": "residual disease site",
                        "requirement": {
                            "requirement_type": "number of sites eligible for local consolidative therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Female patients who:",
                "criterions": [
                    {
                        "exact_snippets": "Female patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Female patients",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or",
                "criterions": [
                    {
                        "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "effective barrier contraception"
                        }
                    },
                    {
                        "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "entire study treatment period and through 4 months after the last dose of study drug"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "effective barrier contraception"
                        }
                    },
                    {
                        "exact_snippets": "Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "entire study treatment period and through 4 months after the last dose of study drug"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Are surgically sterile, OR",
                "criterions": [
                    {
                        "exact_snippets": "Are surgically sterile",
                        "criterion": "surgical sterility",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Are surgically sterile",
                        "criterion": "surgical sterility",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.",
                "criterions": [
                    {
                        "exact_snippets": "Voluntary agreement to provide written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "voluntary agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Voluntary agreement to provide written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "written",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness and ability to comply with all aspects of the protocol",
                        "criterion": "protocol compliance",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness and ability to comply with all aspects of the protocol",
                        "criterion": "protocol compliance",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Voluntary agreement to provide written informed consent",
                                "criterion": "informed consent",
                                "requirement": {
                                    "requirement_type": "voluntary agreement",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Voluntary agreement to provide written informed consent",
                                "criterion": "informed consent",
                                "requirement": {
                                    "requirement_type": "written",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "willingness and ability to comply with all aspects of the protocol",
                                "criterion": "protocol compliance",
                                "requirement": {
                                    "requirement_type": "willingness",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "willingness and ability to comply with all aspects of the protocol",
                                "criterion": "protocol compliance",
                                "requirement": {
                                    "requirement_type": "ability",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. If they are of childbearing potential, agree to use a highly effective method of contraception from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse",
                "criterions": [
                    {
                        "exact_snippets": "of childbearing potential",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agree to use a highly effective method of contraception from the time of signing the informed consent through 4 months after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "agree to use a highly effective method of contraception from the time of signing the informed consent through 4 months after the last dose of study drug",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "from signing informed consent"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "agree to completely abstain from heterosexual intercourse",
                        "criterion": "abstinence from heterosexual intercourse",
                        "requirement": {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirement": {
                        "requirement_type": "status",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "or_criteria": [
                        {
                            "and_criteria": [
                                {
                                    "exact_snippets": "agree to use a highly effective method of contraception from the time of signing the informed consent through 4 months after the last dose of study drug",
                                    "criterion": "contraception use",
                                    "requirement": {
                                        "requirement_type": "method effectiveness",
                                        "expected_value": "highly effective"
                                    }
                                },
                                {
                                    "exact_snippets": "agree to use a highly effective method of contraception from the time of signing the informed consent through 4 months after the last dose of study drug",
                                    "criterion": "contraception use",
                                    "requirement": {
                                        "requirement_type": "duration",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": ">=",
                                                    "value": 0,
                                                    "unit": "from signing informed consent"
                                                },
                                                {
                                                    "operator": "<=",
                                                    "value": 4,
                                                    "unit": "months after last dose"
                                                }
                                            ]
                                        }
                                    }
                                }
                            ]
                        },
                        {
                            "exact_snippets": "agree to completely abstain from heterosexual intercourse",
                            "criterion": "abstinence from heterosexual intercourse",
                            "requirement": {
                                "requirement_type": "abstinence",
                                "expected_value": true
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Serum creatinine ≤ 1.5 × ULN or ≥ 60 mL/minute for subjects with creatinine levels > 1.5 × the institutional ULN",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine ≤ 1.5 × ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "creatinine levels > 1.5 × the institutional ULN ... ≥ 60 mL/minute",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/minute"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum creatinine ≤ 1.5 × ULN",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "creatinine levels > 1.5 × the institutional ULN ... ≥ 60 mL/minute",
                                "criterion": "creatinine clearance",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 60,
                                        "unit": "mL/minute"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.",
                "criterions": [
                    {
                        "exact_snippets": "normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.",
                        "criterion": "QT interval corrected (Fridericia) (QTcF)",
                        "requirement": {
                            "requirement_type": "value in males",
                            "expected_value": {
                                "operator": "<=",
                                "value": 450,
                                "unit": "msec"
                            }
                        }
                    },
                    {
                        "exact_snippets": "normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.",
                        "criterion": "QT interval corrected (Fridericia) (QTcF)",
                        "requirement": {
                            "requirement_type": "value in females",
                            "expected_value": {
                                "operator": "<=",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.",
                        "criterion": "QT interval corrected (Fridericia) (QTcF)",
                        "requirement": {
                            "requirement_type": "value in males",
                            "expected_value": {
                                "operator": "<=",
                                "value": 450,
                                "unit": "msec"
                            }
                        }
                    },
                    {
                        "exact_snippets": "normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of ≤450 milliseconds (msec) in males or ≤470 msec in females.",
                        "criterion": "QT interval corrected (Fridericia) (QTcF)",
                        "requirement": {
                            "requirement_type": "value in females",
                            "expected_value": {
                                "operator": "<=",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Female patients of childbearing potential must have a negative pregnancy test documented at time of screening.",
                "criterions": [
                    {
                        "exact_snippets": "Female patients of childbearing potential",
                        "criterion": "sex and childbearing potential",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Female patients of childbearing potential",
                        "criterion": "sex and childbearing potential",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must have a negative pregnancy test documented at time of screening",
                        "criterion": "pregnancy test result at screening",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "must have a negative pregnancy test documented at time of screening",
                        "criterion": "pregnancy test result at screening",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at time of screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Female patients of childbearing potential",
                            "criterion": "sex and childbearing potential",
                            "requirement": {
                                "requirement_type": "sex",
                                "expected_value": "female"
                            }
                        },
                        {
                            "exact_snippets": "Female patients of childbearing potential",
                            "criterion": "sex and childbearing potential",
                            "requirement": {
                                "requirement_type": "childbearing potential",
                                "expected_value": true
                            }
                        }
                    ]
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "must have a negative pregnancy test documented at time of screening",
                            "criterion": "pregnancy test result at screening",
                            "requirement": {
                                "requirement_type": "test result",
                                "expected_value": "negative"
                            }
                        },
                        {
                            "exact_snippets": "must have a negative pregnancy test documented at time of screening",
                            "criterion": "pregnancy test result at screening",
                            "requirement": {
                                "requirement_type": "timing",
                                "expected_value": "at time of screening"
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "7. Have a known or suspected hypersensitivity to brigatinib or its excipients.",
                "criterions": [
                    {
                        "exact_snippets": "known or suspected hypersensitivity to brigatinib",
                        "criterion": "hypersensitivity to brigatinib",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known or suspected hypersensitivity to ... its excipients",
                        "criterion": "hypersensitivity to brigatinib excipients",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "known or suspected hypersensitivity to brigatinib",
                        "criterion": "hypersensitivity to brigatinib",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known or suspected hypersensitivity to ... its excipients",
                        "criterion": "hypersensitivity to brigatinib excipients",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Decompensated congestive heart failure (CHF) within 6 months prior to first dose of study drug",
                "criterions": [
                    {
                        "exact_snippets": "Decompensated congestive heart failure (CHF) within 6 months prior to first dose of study drug",
                        "criterion": "decompensated congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Decompensated congestive heart failure (CHF) within 6 months prior to first dose of study drug",
                        "criterion": "decompensated congestive heart failure",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to first dose of study drug"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Decompensated congestive heart failure (CHF) within 6 months prior to first dose of study drug",
                        "criterion": "decompensated congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Decompensated congestive heart failure (CHF) within 6 months prior to first dose of study drug",
                        "criterion": "decompensated congestive heart failure",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to first dose of study drug"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Have a known history of human immunodeficiency virus (HIV) infection. Testing is not required in the absence of history.",
                "criterions": [
                    {
                        "exact_snippets": "Have a known history of human immunodeficiency virus (HIV) infection.",
                        "criterion": "history of HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Have a known history of human immunodeficiency virus (HIV) infection.",
                                "criterion": "history of HIV infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Symptomatic CNS metastasis. Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted.",
                "criterions": [
                    {
                        "exact_snippets": "Symptomatic CNS metastasis",
                        "criterion": "CNS metastasis",
                        "requirement": {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    },
                    {
                        "exact_snippets": "Symptomatic CNS metastasis",
                        "criterion": "CNS metastasis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted",
                        "criterion": "CNS disease",
                        "requirement": {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    },
                    {
                        "exact_snippets": "Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted",
                        "criterion": "CNS disease",
                        "requirement": {
                            "requirement_type": "corticosteroid dose requirement",
                            "expected_value": "increasing"
                        }
                    },
                    {
                        "exact_snippets": "Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted",
                        "criterion": "CNS disease",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to study enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Symptomatic CNS metastasis",
                                "criterion": "CNS metastasis",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Symptomatic CNS metastasis",
                                "criterion": "CNS metastasis",
                                "requirement": {
                                    "requirement_type": "symptom status",
                                    "expected_value": "symptomatic"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted",
                                "criterion": "CNS disease",
                                "requirement": {
                                    "requirement_type": "symptom status",
                                    "expected_value": "asymptomatic"
                                }
                            },
                            {
                                "exact_snippets": "Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted",
                                "criterion": "CNS disease",
                                "requirement": {
                                    "requirement_type": "corticosteroid dose requirement",
                                    "expected_value": "increasing"
                                }
                            },
                            {
                                "exact_snippets": "Asymptomatic CNS disease requiring increasing dose of corticosteroids within 7 days prior to study enrollment is also not permitted",
                                "criterion": "CNS disease",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days prior to study enrollment"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose of study drug",
                "criterions": [
                    {
                        "exact_snippets": "Cerebrovascular accident ... within 6 months prior to first dose of study drug",
                        "criterion": "cerebrovascular accident",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "transient ischemic attack within 6 months prior to first dose of study drug",
                        "criterion": "transient ischemic attack",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Cerebrovascular accident ... within 6 months prior to first dose of study drug",
                            "criterion": "cerebrovascular accident",
                            "requirement": {
                                "requirement_type": "time since event",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 6,
                                    "unit": "months"
                                }
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "transient ischemic attack within 6 months prior to first dose of study drug",
                            "criterion": "transient ischemic attack",
                            "requirement": {
                                "requirement_type": "time since event",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 6,
                                    "unit": "months"
                                }
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. The presence of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis at screening.",
                "criterions": [
                    {
                        "exact_snippets": "The presence of pulmonary interstitial disease",
                        "criterion": "pulmonary interstitial disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "The presence of ... drug-related pneumonitis",
                        "criterion": "drug-related pneumonitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "The presence of ... radiation pneumonitis",
                        "criterion": "radiation pneumonitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "The presence of pulmonary interstitial disease",
                        "criterion": "pulmonary interstitial disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "The presence of ... drug-related pneumonitis",
                        "criterion": "drug-related pneumonitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "The presence of ... radiation pneumonitis",
                        "criterion": "radiation pneumonitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Be pregnant, planning a pregnancy, or breastfeeding.",
                "criterions": [
                    {
                        "exact_snippets": "Be pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "planning a pregnancy",
                        "criterion": "pregnancy intention",
                        "requirement": {
                            "requirement_type": "planning pregnancy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Be pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "planning a pregnancy",
                        "criterion": "pregnancy intention",
                        "requirement": {
                            "requirement_type": "planning pregnancy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Have uncontrolled hypertension. Patients with hypertension should be under treatment on study entry to control blood pressure",
                "criterions": [
                    {
                        "exact_snippets": "Have uncontrolled hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    },
                    {
                        "exact_snippets": "Patients with hypertension should be under treatment on study entry to control blood pressure",
                        "criterion": "hypertension treatment",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with hypertension should be under treatment on study entry to control blood pressure",
                        "criterion": "hypertension treatment",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "on study entry"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Have uncontrolled hypertension",
                            "criterion": "hypertension",
                            "requirement": {
                                "requirement_type": "control status",
                                "expected_value": "controlled"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients with hypertension should be under treatment on study entry to control blood pressure",
                                "criterion": "hypertension treatment",
                                "requirement": {
                                    "requirement_type": "treatment status",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Patients with hypertension should be under treatment on study entry to control blood pressure",
                                "criterion": "hypertension treatment",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "on study entry"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:",
                "criterions": [
                    {
                        "exact_snippets": "significant, uncontrolled, or active cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "significant, uncontrolled, or active cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "significant, uncontrolled, or active cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "significant, uncontrolled, or active cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "significant, uncontrolled, or active cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "significant, uncontrolled, or active cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Myocardial infarction (MI) within 6 months prior to the first dose of study drug",
                "criterions": [
                    {
                        "exact_snippets": "Myocardial infarction (MI) within 6 months prior to the first dose of study drug",
                        "criterion": "myocardial infarction (MI)",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to the first dose of study drug"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Myocardial infarction (MI) within 6 months prior to the first dose of study drug",
                        "criterion": "myocardial infarction (MI)",
                        "requirement": {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to the first dose of study drug"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Previously received more than 1 regimen of chemotherapy or immunotherapy for locally advanced or metastatic disease. Note that history of consolidative immunotherapy after concurrent chemoradiotherapy (for locally advanced disease) is allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Previously received more than 1 regimen of chemotherapy or immunotherapy for locally advanced or metastatic disease.",
                        "criterion": "number of prior regimens of chemotherapy or immunotherapy for locally advanced or metastatic disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Previously received more than 1 regimen of chemotherapy or immunotherapy for locally advanced or metastatic disease.",
                        "criterion": "number of prior regimens of chemotherapy or immunotherapy for locally advanced or metastatic disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Any history of ventricular arrhythmia",
                "criterions": [
                    {
                        "exact_snippets": "Any history of ventricular arrhythmia",
                        "criterion": "ventricular arrhythmia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any history of ventricular arrhythmia",
                    "criterion": "ventricular arrhythmia",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "14. Have any condition or illness that, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the study drug.",
                "criterions": [
                    {
                        "exact_snippets": "any condition or illness that, in the opinion of the investigator, would compromise patient safety",
                        "criterion": "condition or illness",
                        "requirement": {
                            "requirement_type": "risk to patient safety",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any condition or illness that, in the opinion of the investigator, would ... interfere with the evaluation of the study drug",
                        "criterion": "condition or illness",
                        "requirement": {
                            "requirement_type": "interference with evaluation of study drug",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "any condition or illness that, in the opinion of the investigator, would compromise patient safety",
                        "criterion": "condition or illness",
                        "requirement": {
                            "requirement_type": "risk to patient safety",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any condition or illness that, in the opinion of the investigator, would ... interfere with the evaluation of the study drug",
                        "criterion": "condition or illness",
                        "requirement": {
                            "requirement_type": "interference with evaluation of study drug",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician",
                "criterions": [
                    {
                        "exact_snippets": "History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician",
                        "criterion": "clinically significant atrial arrhythmia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician",
                        "criterion": "clinically significant atrial arrhythmia",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician",
                        "criterion": "clinically significant atrial arrhythmia",
                        "requirement": {
                            "requirement_type": "determined by",
                            "expected_value": "treating physician"
                        }
                    },
                    {
                        "exact_snippets": "clinically significant bradyarrhythmia ... as determined by the treating physician",
                        "criterion": "clinically significant bradyarrhythmia",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant bradyarrhythmia ... as determined by the treating physician",
                        "criterion": "clinically significant bradyarrhythmia",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant bradyarrhythmia ... as determined by the treating physician",
                        "criterion": "clinically significant bradyarrhythmia",
                        "requirement": {
                            "requirement_type": "determined by",
                            "expected_value": "treating physician"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician",
                                "criterion": "clinically significant atrial arrhythmia",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician",
                                "criterion": "clinically significant atrial arrhythmia",
                                "requirement": {
                                    "requirement_type": "clinical significance",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "History of clinically significant atrial arrhythmia (including clinically significant bradyarrhythmia), as determined by the treating physician",
                                "criterion": "clinically significant atrial arrhythmia",
                                "requirement": {
                                    "requirement_type": "determined by",
                                    "expected_value": "treating physician"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "clinically significant bradyarrhythmia ... as determined by the treating physician",
                                "criterion": "clinically significant bradyarrhythmia",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "clinically significant bradyarrhythmia ... as determined by the treating physician",
                                "criterion": "clinically significant bradyarrhythmia",
                                "requirement": {
                                    "requirement_type": "clinical significance",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "clinically significant bradyarrhythmia ... as determined by the treating physician",
                                "criterion": "clinically significant bradyarrhythmia",
                                "requirement": {
                                    "requirement_type": "determined by",
                                    "expected_value": "treating physician"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Previously received any prior TKI, including ALK-targeted TKIs. Note: on-going first-line brigatinib use as specified in the Inclusion criteria is allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Previously received any prior TKI, including ALK-targeted TKIs.",
                        "criterion": "prior TKI therapy",
                        "requirement": {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "on-going first-line brigatinib use as specified in the Inclusion criteria is allowed.",
                        "criterion": "on-going first-line brigatinib use",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Previously received any prior TKI, including ALK-targeted TKIs.",
                                "criterion": "prior TKI therapy",
                                "requirement": {
                                    "requirement_type": "history of use",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "on-going first-line brigatinib use as specified in the Inclusion criteria is allowed.",
                                    "criterion": "on-going first-line brigatinib use",
                                    "requirement": {
                                        "requirement_type": "current use",
                                        "expected_value": true
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging)",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging)",
                        "criterion": "spinal cord compression",
                        "requirement": {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with leptomeningeal disease and without cord compression are allowed",
                        "criterion": "leptomeningeal disease without cord compression",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with leptomeningeal disease and without cord compression are allowed",
                        "criterion": "leptomeningeal disease without cord compression",
                        "requirement": {
                            "requirement_type": "spinal cord compression",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging)",
                                "criterion": "spinal cord compression",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging)",
                                "criterion": "spinal cord compression",
                                "requirement": {
                                    "requirement_type": "current",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients with leptomeningeal disease and without cord compression are allowed",
                                "criterion": "leptomeningeal disease without cord compression",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Patients with leptomeningeal disease and without cord compression are allowed",
                                "criterion": "leptomeningeal disease without cord compression",
                                "requirement": {
                                    "requirement_type": "spinal cord compression",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "5. Serum total bilirubin less than or equal to ≤ 1.5 × ULN or direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 × ULN",
                "criterions": [
                    {
                        "exact_snippets": "Serum total bilirubin less than or equal to ≤ 1.5 × ULN",
                        "criterion": "serum total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 × ULN",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Serum total bilirubin less than or equal to ≤ 1.5 × ULN",
                        "criterion": "serum total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "condition": {
                            "exact_snippets": "Serum total bilirubin less than or equal to ≤ 1.5 × ULN",
                            "criterion": "serum total bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": ">",
                                    "value": 1.5,
                                    "unit": "ULN"
                                }
                            }
                        },
                        "then_criteria": {
                            "exact_snippets": "direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 × ULN",
                            "criterion": "direct bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 1,
                                    "unit": "ULN"
                                }
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Documented ALK re-arrangement as detected by: (1) FISH, (2) IHC, (3) tissue NGS, or (4) cfDNA NGS",
                "criterions": [
                    {
                        "exact_snippets": "Documented ALK re-arrangement",
                        "criterion": "ALK re-arrangement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "as detected by: (1) FISH, (2) IHC, (3) tissue NGS, or (4) cfDNA NGS",
                        "criterion": "ALK re-arrangement detection method",
                        "requirement": {
                            "requirement_type": "detection method",
                            "expected_value": [
                                "FISH",
                                "IHC",
                                "tissue NGS",
                                "cfDNA NGS"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Histologically or cytologically confirmed diagnosis of stage IV NSCLC (or recurrent NSCLC not a candidate for definitive multimodality therapy)",
                "criterions": [
                    {
                        "exact_snippets": "Histologically or cytologically confirmed diagnosis",
                        "criterion": "NSCLC diagnosis confirmation",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "stage IV NSCLC",
                        "criterion": "NSCLC stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    },
                    {
                        "exact_snippets": "recurrent NSCLC not a candidate for definitive multimodality therapy",
                        "criterion": "recurrent NSCLC eligibility for definitive multimodality therapy",
                        "requirement": {
                            "requirement_type": "eligibility for definitive multimodality therapy",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "8. Activated PTT (aPTT) ≤ 1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant",
                "criterions": [
                    {
                        "exact_snippets": "Activated PTT (aPTT) ≤ 1.5 × ULN",
                        "criterion": "activated partial thromboplastin time (aPTT)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant",
                        "criterion": "prothrombin time (PT) or partial thromboplastin time (PTT) in subjects receiving anticoagulant therapy",
                        "requirement": {
                            "requirement_type": "therapeutic range",
                            "expected_value": "within therapeutic range of intended use of anticoagulant"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "not_criteria": {
                        "not_criteria": {
                            "exact_snippets": "unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant",
                            "criterion": "prothrombin time (PT) or partial thromboplastin time (PTT) in subjects receiving anticoagulant therapy",
                            "requirement": {
                                "requirement_type": "therapeutic range",
                                "expected_value": "within therapeutic range of intended use of anticoagulant"
                            }
                        }
                    }
                },
                "then_criteria": {
                    "exact_snippets": "Activated PTT (aPTT) \u0013 1.5 \u0013 ULN",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirement": {
                        "requirement_type": "quantity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 1.5,
                            "unit": "ULN"
                        }
                    }
                },
                "else_criteria": {
                    "exact_snippets": "unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulant",
                    "criterion": "prothrombin time (PT) or partial thromboplastin time (PTT) in subjects receiving anticoagulant therapy",
                    "requirement": {
                        "requirement_type": "therapeutic range",
                        "expected_value": "within therapeutic range of intended use of anticoagulant"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "6. Males or females aged at least 18 years.",
                "criterions": [
                    {
                        "exact_snippets": "Males or females",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "aged at least 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum_age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Platelet count at least 75,000/mm3 or at least 75 x 109/L",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count at least 75,000/mm3 or at least 75 x 10^9/L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 75000,
                                        "unit": "mm3"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 75,
                                        "unit": "10^9/L"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Platelet count at least 75,000/mm3",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mm3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelet count at least 75 x 10^9/L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "8. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition that could affect oral absorption of the study drug.",
                "criterions": [
                    {
                        "exact_snippets": "malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "other gastrointestinal (GI) illness or condition that could affect oral absorption of the study drug",
                        "criterion": "gastrointestinal illness or condition affecting oral absorption",
                        "requirement": {
                            "requirement_type": "effect on oral absorption",
                            "expected_value": "could affect oral absorption of the study drug"
                        }
                    },
                    {
                        "exact_snippets": "other gastrointestinal (GI) illness or condition that could affect oral absorption of the study drug",
                        "criterion": "gastrointestinal illness or condition affecting oral absorption",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "malabsorption syndrome",
                        "criterion": "malabsorption syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "other gastrointestinal (GI) illness or condition that could affect oral absorption of the study drug",
                                "criterion": "gastrointestinal illness or condition affecting oral absorption",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "other gastrointestinal (GI) illness or condition that could affect oral absorption of the study drug",
                                "criterion": "gastrointestinal illness or condition affecting oral absorption",
                                "requirement": {
                                    "requirement_type": "effect on oral absorption",
                                    "expected_value": "could affect oral absorption of the study drug"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Unstable angina within 6 months prior to first dose of study drug",
                "criterions": [
                    {
                        "exact_snippets": "Unstable angina within 6 months prior to first dose of study drug",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Unstable angina within 6 months prior to first dose of study drug",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to first dose of study drug"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Unstable angina within 6 months prior to first dose of study drug",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Unstable angina within 6 months prior to first dose of study drug",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to first dose of study drug"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Have an ongoing or active infection, including, but not limited to, the requirement for intravenous (IV) antibiotics.",
                "criterions": [
                    {
                        "exact_snippets": "Have an ongoing or active infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "requirement for intravenous (IV) antibiotics",
                        "criterion": "intravenous (IV) antibiotics",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitively relapse-free with at least 2 years elapsed since the diagnosis of the other primary malignancy.",
                "criterions": [
                    {
                        "exact_snippets": "Have been diagnosed with another primary malignancy other than NSCLC",
                        "criterion": "diagnosis of another primary malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "except for adequately treated non-melanoma skin cancer",
                        "criterion": "non-melanoma skin cancer",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    },
                    {
                        "exact_snippets": "except for adequately treated ... cervical cancer in situ",
                        "criterion": "cervical cancer in situ",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    },
                    {
                        "exact_snippets": "definitively treated non-metastatic prostate cancer",
                        "criterion": "non-metastatic prostate cancer",
                        "requirement": {
                            "requirement_type": "treatment status",
                            "expected_value": "definitively treated"
                        }
                    },
                    {
                        "exact_snippets": "patients with another primary malignancy who are definitively relapse-free with at least 2 years elapsed since the diagnosis of the other primary malignancy",
                        "criterion": "other primary malignancy",
                        "requirement": {
                            "requirement_type": "relapse status",
                            "expected_value": "definitively relapse-free"
                        }
                    },
                    {
                        "exact_snippets": "patients with another primary malignancy who are definitively relapse-free with at least 2 years elapsed since the diagnosis of the other primary malignancy",
                        "criterion": "other primary malignancy",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Have been diagnosed with another primary malignancy other than NSCLC",
                                "criterion": "diagnosis of another primary malignancy",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "or_criteria": [
                                        {
                                            "exact_snippets": "except for adequately treated non-melanoma skin cancer",
                                            "criterion": "non-melanoma skin cancer",
                                            "requirement": {
                                                "requirement_type": "treatment status",
                                                "expected_value": "adequately treated"
                                            }
                                        },
                                        {
                                            "exact_snippets": "except for adequately treated ... cervical cancer in situ",
                                            "criterion": "cervical cancer in situ",
                                            "requirement": {
                                                "requirement_type": "treatment status",
                                                "expected_value": "adequately treated"
                                            }
                                        },
                                        {
                                            "exact_snippets": "definitively treated non-metastatic prostate cancer",
                                            "criterion": "non-metastatic prostate cancer",
                                            "requirement": {
                                                "requirement_type": "treatment status",
                                                "expected_value": "definitively treated"
                                            }
                                        },
                                        {
                                            "and_criteria": [
                                                {
                                                    "exact_snippets": "patients with another primary malignancy who are definitively relapse-free with at least 2 years elapsed since the diagnosis of the other primary malignancy",
                                                    "criterion": "other primary malignancy",
                                                    "requirement": {
                                                        "requirement_type": "relapse status",
                                                        "expected_value": "definitively relapse-free"
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "patients with another primary malignancy who are definitively relapse-free with at least 2 years elapsed since the diagnosis of the other primary malignancy",
                                                    "criterion": "other primary malignancy",
                                                    "requirement": {
                                                        "requirement_type": "time since diagnosis",
                                                        "expected_value": {
                                                            "operator": ">=",
                                                            "value": 2,
                                                            "unit": "years"
                                                        }
                                                    }
                                                }
                                            ]
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}